Posted by Michael Wonder on 22 May 2023
Satsuma Pharmaceuticals announces FDA acceptance of 505(b)(2) NDA for STS101, a novel and investigational dihydroergotamine nasal powder product for the acute treatment of migraine
18 May 2023 - January 2024 PDUFA date expected.
Satsuma Pharmaceuticals today announced that its 505(b)(2) new drug application for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.
